ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

KRAS G12D Inhibitor KQB548

Also written as “BAY 3771249” and “KQB548”.

Its studies are led by 2 companies.

Furthest: phase 1, since Apr 1, 20262 company-led studies, 2 open or runningNext primary completion: Jul 27, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayerits history only11 open or runningphase 1since Apr 1, 2026Apr 1, 2026Jul 27, 2029phase 1 · NCT07535112
Kumquat Biosciencesits history only11 open or runningphase 1since Sep 3, 2025Sep 3, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2025First study: phase 1 study in Solid Tumor MalignanciesNew to Kumquat BiosciencesKumquat Biosciences · NCT07207707 · 78 planned · United States
  2. Apr 1, 2026Bayer’s first study: phase 1 study in Advanced/Metastatic Colorectal AdenocarcinomaNew to BayerBayer · NCT07535112 · 130 planned · United States, Australia, Belgium and more

Ahead

  1. Jul 27, 2029Primary completion: phase 1 study in Advanced/Metastatic Colorectal AdenocarcinomaBayer · NCT07535112

TargetBeta

KRAS →read by rule
“An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07535112Advanced/Metastatic Colorectal Adenocarcinoma · United States, Australia, Belgium and more1RecruitingBayerJul 27, 2029130
NCT07207707Solid Tumor Malignancies · United States1RecruitingKumquat BiosciencesSep 202678

How it is read

Names in the registry

  • “BAY 3771249”, 1 entry
  • “KQB548”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.